Euclidean Capital is an investment fund managing more than $796 billion ran by Joseph Cosmai. There are currently 10 companies in Mr. Cosmai’s portfolio. The largest investments include Spdr Sp 500 Etf Tr and Ishares Tr, together worth $759 billion.
As of 7th August 2024, Euclidean Capital’s top holding is 1,146,979 shares of Spdr Sp 500 Etf Tr currently worth over $624 billion and making up 78.4% of the portfolio value.
In addition, the fund holds 2,425,144 shares of Ishares Tr worth $135 billion.
The third-largest holding is Foghorn Therapeutics worth $9.05 billion and the next is Oric Pharmaceuticals worth $7 billion, with 989,410 shares owned.
Currently, Euclidean Capital's portfolio is worth at least $796 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Euclidean Capital office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Joseph Cosmai serves as the Manager at Euclidean Capital.
In the most recent 13F filing, Euclidean Capital revealed that it had opened a new position in
Surrozen Inc and bought 87,696 shares worth $960 million.
The investment fund also strengthened its position in Spdr Sp 500 Etf Tr by buying
900,729 additional shares.
This makes their stake in Spdr Sp 500 Etf Tr total 1,146,979 shares worth $624 billion.
On the other hand, there are companies that Euclidean Capital is getting rid of from its portfolio.
Euclidean Capital closed its position in Spdr Gold Tr on 14th August 2024.
It sold the previously owned 1,062,500 shares for $182 billion.
The two most similar investment funds to Euclidean Capital are Van Cleef Asset Management,inc and Unison Advisors. They manage $795 billion and $797 billion respectively.
Euclidean Capital’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 3.5% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $429 million.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Spdr Sp 500 Etf Tr |
365.78%
1,146,979
|
$624,208,911,000 | 78.43% |
| Spdr Gold Tr |
Closed
1,062,500
|
$182,165,625,000 | |
| Ishares Tr |
No change
2,425,144
|
$135,274,532,000 | 17.00% |
| Foghorn Therapeutics Inc. |
No change
1,573,761
|
$9,049,126,000 | 1.14% |
| Oric Pharmaceuticals, Inc. |
No change
989,410
|
$6,995,129,000 | 0.88% |
| Alector, Inc. |
No change
1,307,858
|
$5,937,675,000 | 0.75% |
| Pmv Pharmaceuticals Inc |
No change
2,627,643
|
$4,256,782,000 | 0.53% |
| 23andme Holding Co |
No change
10,243,122
|
$4,007,109,000 | 0.50% |
| Tenaya Therapeutics Inc |
No change
1,015,705
|
$3,148,686,000 | 0.40% |
| RAPT Therapeutics, Inc. |
No change
657,899
|
$2,006,592,000 | 0.25% |
| Ngm Biopharmaceuticals Inc |
Closed
992,168
|
$1,061,620,000 | |
| Surrozen Inc |
Opened
87,696
|
$960,271,000 | 0.12% |
| Surrozen Inc |
Closed
1,315,463
|
$644,577,000 | |
| No transactions found | |||
| Showing first 500 out of 13 holdings | |||